What is Inflammatix?
Inflammatix is fundamentally transforming the landscape of clinical diagnostics by shifting the focus from pathogen detection to host-response analysis. By reading the patient's immune system, the company provides rapid, actionable insights that are critical for managing acute infections and sepsis. This molecular diagnostic platform is designed to reduce public health burdens by enabling physicians to deliver precise, timely treatments. Positioned at the intersection of biotechnology and artificial intelligence, Inflammatix is scaling its operations to address urgent clinical needs, moving beyond traditional diagnostic limitations to improve patient outcomes in high-acuity settings.
How much funding has Inflammatix raised?
Inflammatix has raised a total of $216.5M across 6 funding rounds:
Other Financing Round
$6M
Series C
$32M
Grant
$7.4M
Series D
$102M
Grant
$12.1M
Series E
$57M
Other Financing Round (2019): $6M with participation from Biomedical Advanced Research and Development Authority (BARDA)
Series C (2020): $32M led by Grey Sky Venture Partners, Think.Health Ventures, Northpond Ventures, and Khosla Ventures
Grant (2020): $7.4M supported by Biomedical Advanced Research and Development Authority
Series D (2021): $102M featuring Think.Health, Northpond Ventures, OSF Healthcare Ventures, Khosla Ventures, and D1 Capital Partners
Grant (2021): $12.1M backed by Biomedical Advanced Research and Development Authority (BARDA
Series E (2024): $57M with participation from Northpond Ventures, Think.Health Ventures, D1 Capital Partners Master, Iberis Capital, and Khosla Ventures
Key Investors in Inflammatix
Khosla Ventures
A prominent venture capital firm founded by Vinod Khosla, focusing on breakthrough technologies across health, AI, and enterprise sectors with over fourteen billion dollars under management.
Northpond Ventures
A science-driven venture firm dedicated to advancing breakthrough innovations that create significant, positive impacts on humanity and the scientific landscape.
D1 Capital Partners Master
A New York-based investment firm operating within the venture capital and private equity space, known for its strategic participation in high-growth technology and healthcare ventures.
What's next for Inflammatix?
With the successful closure of this major strategic investment, Inflammatix is well-positioned to accelerate its clinical development pipeline and expand its commercial footprint. The company's roadmap focuses on the regulatory advancement of its diagnostic tests and the integration of its technology into standard hospital workflows. As it transitions from a research-heavy phase to a scaling enterprise, the firm will likely prioritize the expansion of its biomarker library and the enhancement of its machine learning algorithms. This capital injection provides the necessary runway to navigate the complexities of FDA approval processes and establish a dominant market presence in the global diagnostics sector.
See full Inflammatix company page
